Identifying patients with severe aortic stenosis who could potentially benefit from transcatheter aortic valve replacement (TAVR) is very important—but managing and tracking them over time can be quite a challenge.

When the ACC and AHA collaborated on new valvular heart disease guidelines in 2020, the two groups highlighted the importance of interventional treatment options such as TAVR. However, an estimated one-third of patients with severe aortic stenosis in the U.S. still lack a guideline-recommended treatment plan.

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more. 

The veteran interventional cardiologist told Cardiovascular Business he sees potential in the ACC's ability to grow both nationally and internationally in the next year. 

The third and final day of ACC.23 featured a key update on Medtronic's pulsed-field ablation technology and many other late-breaking clinical studies. 

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

One key takeaway was that women faced a higher MI risk than men, but only for the first 30 days.